Talis Biomedical Corporation Common Stock
TLIS
TLIS was delisted on the 30th of August, 2024.
19 hedge funds and large institutions have $4.27M invested in Talis Biomedical Corporation Common Stock in 2023 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 8 increasing their positions, 4 reducing their positions, and 7 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
14% less funds holding
Funds holding: 22 → 19 (-3)
19% less capital invested
Capital invested by funds: $5.27M → $4.27M (-$997K)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Prelude Capital Management
New York
|
+$102K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$78.4K |
| 3 |
Citigroup
New York
|
+$36K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$13.1K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$5.21K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$43.9K |
| 2 |
Renaissance Technologies
New York
|
-$26K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$23.5K |
| 4 |
State Street
Boston,
Massachusetts
|
-$22.8K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$18.7K |
TLIS Hedge Fund Activity: Q3 2023 in Review
19 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Talis Biomedical Corporation Common Stock (TLIS) for Q3 2023, worth a combined $4.27M — down 19% from $5.27M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of TLIS and 4 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 8 added.
The largest buyer was Prelude Capital Management, opening a new position worth an estimated $102K. The largest seller was Millennium Management, exiting entirely with an estimated $43.9K sold.
- 19 institutional investors held Talis Biomedical Corporation Common Stock (TLIS) as of Q3 2023, down from 22 in Q2 2023.
- Funds reported $4.27M of Talis Biomedical Corporation Common Stock stock for Q3 2023, down 19% quarter-over-quarter.
- 4 funds opened new Talis Biomedical Corporation Common Stock positions in Q3 2023 and 7 closed out, a net change of -3 holders.
- The largest Talis Biomedical Corporation Common Stock buyer in Q3 2023 was Prelude Capital Management, an estimated $102K added.
- The largest Talis Biomedical Corporation Common Stock seller in Q3 2023 was Millennium Management, an estimated $43.9K sold.
Based on aggregated 13F filings for Q3 2023.